PubMed Health⌕ Search

PubMed · 12662729

The recursive deterministic perceptron neural network.

Abstract

We introduce a feedforward multilayer neural network which is a generalization of the single layer perceptron topology (SLPT), called recursive deterministic perceptron (RDP). This new model is capable of solving any two-class classification problem, as opposed to the single layer perceptron which can only solve classification problems dealing with linearly separable sets (two subsets X and Y of R(d) are said to be linearly separable if there exists a hyperplane such that the elements of X and Y lie on the two opposite sides of R(d) delimited by this hyperplane). We propose several growing methods for constructing a RDP. These growing methods build a RDP by successively adding intermediate neurons (IN) to the topology (an IN corresponds to a SLPT). Thus, as a result, we obtain a multilayer perceptron topology, which together with the weights, are determined automatically by the constructing algorithms. Each IN augments the affine dimension of the set of input vectors. This augmentation is done by adding the output of each of these INs, as a new component, to every input vector. The construction of a new IN is made by selecting a subset from the set of augmented input vectors which is LS from the rest of this set. This process ends with LS classes in almost n-1 steps where n is the number of input vectors. For this construction, if we assume that the selected LS subsets are of maximum cardinality, the problem is proven to be NP-complete. We also introduce a generalization of the RDP model for classification of m classes (m>2) allowing to always separate m classes. This generalization is based on a new notion of linear separability for m classes, and it follows naturally from the RDP. This new model can be used to compute functions with a finite domain, and thus, to approximate continuous functions. We have also compared - over several classification problems - the percentage of test data correctly classified, or the topology of the 2 and m classes RDPs with that of the backpropagation (BP), cascade correlation (CC), and two other growing methods.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Mohamed Tajine, David Elizondo. 1998. The recursive deterministic perceptron neural network.. https://doi.org/10.1016/s0893-6080(98)00054-9

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗